Previous 10 | Next 10 |
Gainers: Bright Health Group BHG +21%. TransMedics Group TMDX +21%. Belite Bio (BLTE) +11%. Sharps Technology STSS +11%. Immutep (IMMP) +7%. Losers: Connect Biopharma CNTB -45%. Amarin AMRN -43%. Kezar Life Sciences (KZR) -35%. MacroGenic...
Shares of Amarin Corp. (NASDAQ:AMRN) are down 23% in premarket trading after reporting Q1 2022 results that missed on the top and bottom lines and continuing to suspend its 2022 revenue guidance. The company's net loss widened more than 18 times to -$31.6M from -$1.6M in the year-ag...
Amarin press release (NASDAQ:AMRN): Q1 Non-GAAP EPS of -$0.06 misses by $0.05. Revenue of $94.6M (-33.5% Y/Y) misses by $33.61M. As of March 31, 2022, Amarin reported aggregate cash and investments of $389.3 million, consisting of cash and cash equivalents of $219.2 million and liquid short-t...
Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Continued Progress on Go-To-Market Strategy in the US Plans for ...
Amarin (NASDAQ:AMRN) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate is $128.21M (-9.8% Y/Y). Over the last 2 years, AMRN has beaten EPS estimates 88% of the time and has beate...
The latest prespecified and post hoc sub-analysis of the landmark REDUCE-IT ® study, published today in the Journal of the American College of Cardiology (JACC), demonstrated that VASCEPA ® (icosapent ethyl) significantly reduces the total ischemic ev...
DUBLIN, Ireland and BRIDGEWATER, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today its partner HLS Therapeutics has completed negotiations with Canada’s pan-Canadian Pharmaceutical Alliance (pCPA) for the terms and conditions under which VA...
Amarin has had a rough go of it since the patent ruling in the United States for their flagship product, Vascepa. The company is struggling to maintain growth as generics. The company is banking on the European markets to drive growth in the coming years. U.S. generics might have a ha...
There are a number of interesting developments at Amarin. These may enable Amarin to regain ground it lost due to an unconscionable court ruling a few years ago. The stock is depressed now, but if any of these developments pan out, it should start moving again. For further d...
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's first quarter 2022 financial results on Wednesda...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...